Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | G6PD | P11413 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14993457 | 0.83 | CYP3A4 (0.53) | KDM4EALDH1A1HSD17B10POLBMAPK1 | |
| SCHEMBL11816616 | 0.83 | ALDH1A1 (0.46) | KDM4EALDH1A1HSD17B10MAPK1MAPT | |
| SCHEMBL23455410 | 0.81 | RXRA (0.53) | KDM4EALDH1A1HSD17B10POLBMAPK1 | |
| SCHEMBL3769042 | 0.81 | MAPT (0.49) | KDM4EALDH1A1MAPK1GAAMAPT | |
| SCHEMBL7282028 | 0.81 | CYP3A4 (0.55) | KDM4EALDH1A1HSD17B10POLBGAA | |
| SCHEMBL27683482 | 0.78 | CYP3A4 (0.53) | POLBMAPK1KMT2ADPP4USP2 | |
| SCHEMBL1458505 | 0.78 | SMN1; SMN2 (0.46) | KDM4EALDH1A1POLBMAPTKMT2A | |
| SCHEMBL14818820 | 0.78 | PLK1 (0.48) | KDM4EALDH1A1GAAMAPTKMT2A | |
| SCHEMBL28154597 | 0.78 | KMT2A (0.49) | POLBKMT2APTGS1CYP3A4 | |
| SCHEMBL14352988 | 0.77 | ALDH2 (0.46) | KDM4EALDH1A1HSD17B10MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116502-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | The Regents Of The University Of Michigan (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015138326-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20150250769-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-09-10 | — | — | US | disclosed |
| EP-1951708-B1 | PIPERAZINE DERIVATIVE USEFUL AS A CCR5 ANTAGONIST | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1632479-B1 | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives | SCHERING CORP (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1632479-B1 | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives | SCHERING CORP (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1175401-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066558-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| US-5597841-A | 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP, INC. (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0594257-B1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC (US) | 1996-07-10 | — | — | EP | disclosed |
| US-5512589-A | TREATING DEGENERATIVE DISEASES | STERLING WINTHROP INC. (US) | 1996-04-30 | — | — | US | disclosed |
| EP-0594257-A1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1994-04-27 | — | — | EP | disclosed |
| US-5306818-A | Treating degenerative diseases such as emphysema, rheumatoid arthritis and pancreatitis | STERLING WINTHROP INC. (US) | 1994-04-26 | — | — | US | disclosed |
| US-5250696-A | Treatment of degenerative diseases | STERLING WINTHROP INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-5128339-A | Emphysema, rheumatoid arthritis, pancreatitis | STERLING WINTHROP INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0483928-A1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use | STERLING WINTHROP INC. (US) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250769-A1 | METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS | RHOA, ARHGEF1, ARHGEF2 | KDM4E 2620/4885ALDH1A1 4467/4885HSD17B10 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.